Market Synopsis of Mitochondrial Myopathies Market:
The Mitochondrial Myopathies Market is anticipated to reach USD 821.7 Million by 2030 at 5.3% CAGR during the forecast period 2022-2030
Mitochondrial myopathy is an umbrella term for rare genetic diseases caused due to defective mitochondria in cells which results in inability of the mitochondria to consume normal levels of oxygen and produce energy. The disease manifests itself from infancy to adulthood.
The market driving factors for Mitochondrial myopathies Market are the growing number of cases that are detected, rising number of screening for genetic diseases, incentives provided by governments for rare genetic diseases etc. The market restraints are the poor number of treatment options due to rare nature of the disease, absence of curative treatment etc.
Figure 1 Mitochondrial myopathies Market by Type, 2016 (% Market Share)
The mitochondrial myopathies market is segmented on the basis of type and therapies. Based on type, the market has been segmented as Kearns-Sayre syndrome (KSS), Leigh syndrome, Mitochondrial DNA depletion syndrome (MDS), Mitochondrial encephalomyopathy, Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), Myoclonus epilepsy with ragged red fibers (MERRF), Neuropathy, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, Progressive external ophthalmoplegia (PEO). Based on the therapies, the market has been segmented as dietary, supportive, vitamins, coenzymes and antioxidants and other.
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is the fastest region because of large unmet needs which is led by China and India. The Middle East and Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions.
Key players of Mitochondrial myopathies Market:
Key players profiled in the Mitochondrial myopathies Market report are Reata Pharmaceuticals, Inc., Stealth BioTherapeutics, Raptor Pharmaceutical Corp., GeneDx, NeuroVive Pharmaceutical AB, and others. The report for mitochondrial myopathies market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The Mitochondrial myopathies Market report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Mitochondrial myopathies market valuation can touch USD 821.7 Million by 2030.
Mitochondrial myopathies market can exhibit a CAGR of 5.3% from 2022 to 2030.
Screening tests for genetic diseases, increasing prevalence of mitochondrial myopathies, and incentives by governments for finding solutions are major drivers of the global mitochondrial myopathies market.
Limited treatment options and absence of curative treatment can hamper the global mitochondrial myopathies market growth.
The Americas can dominate the global mitochondrial myopathies market owing to favorable reimbursement schemes and large healthcare expenditure.
Stealth BioTherapeutics, Raptor Pharmaceutical Corp., Reata Pharmaceuticals, Inc., GeneDx, NeuroVive Pharmaceutical AB, and others are notable players of the global mitochondrial myopathies market.